Arena Pharmaceuticals to Report First Quarter 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, April 18, 2007 SAN DIEGO, April 11, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced it will report first
SAN DIEGO and WOODCLIFF LAKE, N.J., Oct. 6, 2010 /PRNewswire via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) and Eisai Inc. announced today upcoming lorcaserin presentations at Obesity 2010, the 28th Annual Scientific Meeting of The Obesity Society, in San Diego, California.
SAN DIEGO, and WOODCLIFF LAKE, N.J., Sept 16, 2010 /PRNewswire via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) and Eisai Inc. announced today that the US Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee voted 9 to 5 that the available
- Appoints Kevin R. Lind as President and Chief Executive Officer of Arena Neuroscience, Inc. - Appoints Laurie D. Stelzer as Executive Vice President and Chief Financial Officer of Arena - Expects to deliver up to eight major data readouts between 2020-21 and multiple INDs - Progressing first- or
Arena Pharmaceutcals raises IPO to 6 mln shares WASHINGTON, July 25 (Reuters) - Arena Pharmaceuticals Inc. on Tuesday raised its initial public offering (IPO) to 6 million shares of common stock from 5 million shares. The company, which says it has developed technology that identifies drug